We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+11.54%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$359M
AUM Growth
+$47.7M
Cap. Flow
+$72.2M
Cap. Flow %
20.13%
Top 10 Hldgs %
73.89%
Holding
44
New
12
Increased
4
Reduced
14
Closed
8

Top Buys

Rank Stock Value
1
NKTX icon
Nkarta
NKTX
+$60M
2
CVAC
CureVac
CVAC
+$20.7M
3
COGT icon
Cogent Biosciences
COGT
+$14.8M
4
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$9.03M
5
EQ icon
Equillium
EQ
+$8.7M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$20.5M
2
SWTX
SpringWorks Therapeutics
SWTX
+$6.79M
3
ARAV
Aravive, Inc. Common Stock
ARAV
+$6.71M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$5.28M
5
PVLA
Palvella Therapeutics
PVLA
+$5.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FMTX
1
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$74.4M 20.74%
1,492,163
-86,225
-5% -$3.48M
NKTX icon
2
Nkarta
NKTX
$162M
$61.2M 17.06%
+2,034,703
New +$60M
ISEE
3
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$19M 5.3%
3,370,478
– –
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$19M 5.29%
398,017
-159,339
-29% -$6.79M
CVAC
5
DELISTED
CureVac
CVAC
$17.2M 4.81%
+370,385
New +$20.7M
STRO icon
6
Sutro Biopharma
STRO
$398M
$16.8M 4.7%
167,558
– –
ICPT
7
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$16.7M 4.67%
403,688
– –
ALLK
8
DELISTED
Allakos
ALLK
$15.7M 4.37%
192,334
-51,534
-21% -$4.18M
COGT icon
9
Cogent Biosciences
COGT
$6.91B
$13.3M 3.71%
+1,420,455
New +$14.8M
SYRS
10
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$11.6M 3.24%
140,795
-16,395
-10% -$1.86M
ODT
11
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$11M 3.05%
815,421
+318,916
+64% +$9.03M
BCEL
12
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$8.63M 2.41%
617,560
+107,264
+21% +$1.6M
VRNA
13
DELISTED
Verona Pharma
VRNA
$6.93M 1.93%
1,111,112
+1,067,656
+2,457% +$7.38M
SYRE icon
14
Spyre Therapeutics
SYRE
$8.69B
$6.27M 1.75%
35,349
-3,351
-9% -$620K
EQ icon
15
Equillium
EQ
$156M
$6.2M 1.73%
+1,074,285
New +$8.7M
ACRS icon
16
Aclaris Therapeutics
ACRS
$750M
$5.53M 1.54%
2,153,265
-454,852
-17% -$1.02M
TNGX icon
17
Tango Therapeutics
TNGX
$4.35B
$5.18M 1.44%
+500,000
New +$5.11M
RYTM icon
18
Rhythm Pharmaceuticals
RYTM
$7.28B
$5.09M 1.42%
234,846
-41,443
-15% -$950K
PANA.U
19
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$4.8M 1.34%
+400,000
New +$4.6M
ALPN
20
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.34M 1.21%
+494,190
New +$4.52M
KALA icon
21
KALA BIO
KALA
$12.5M
$3.38M 0.94%
181
+45
+33% +$1.03M
ALBO
22
DELISTED
Albireo Pharma Inc
ALBO
$3.34M 0.93%
+100,000
New +$2.91M
GERN icon
23
Geron
GERN
$949M
$2.66M 0.74%
1,531,088
-2,359,132
-61% -$4.36M
KLRS
24
Kalaris Therapeutics
KLRS
$85.2M
$2.5M 0.7%
+3,959
New +$2.7M
NVAX icon
25
Novavax
NVAX
$1.23B
$2.35M 0.65%
+21,660
New +$2.64M
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q3 2020 Portfolio in Review

As of Q3 2020, Samsara BioCapital held 44 positions worth $359M, up 15% from $311M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Samsara BioCapital deployed $72.2M of net new capital in Q3 2020, opening 12 new positions and adding to 4 existing holdings. Its largest new stake was Nkarta: 2,034,703 shares worth $61.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $6.79M trimmed.

  • Samsara BioCapital's largest Q3 2020 buy was Nkarta: 2,034,703 shares worth $61.2M.
  • Samsara BioCapital added most to Odonate Therapeutics, Inc. Common Stock in Q3 2020, an estimated $9.03M increase.
  • Samsara BioCapital's biggest Q3 2020 reduction was SpringWorks Therapeutics, cutting an estimated $6.79M.
  • Samsara BioCapital fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $20.5M.
  • Samsara BioCapital's ten largest holdings make up 74% of its $359M portfolio in Q3 2020.
  • Samsara BioCapital opened 12 new positions and closed 8 in Q3 2020.
  • Samsara BioCapital's portfolio value rose 15% quarter-over-quarter to $359M.

Based on Samsara BioCapital's 13F filing for Q3 2020, filed 16 Nov 2020.